Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$38.57M, compared with -$16.55M a year earlier. Trailing-twelve-month EBITDA was -$158.55M.
Context
- EBITDA amounted to 4881.5% of revenue in FY2025, up 4686.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$50.51M (+63.0%) for the fiscal year ending Dec 2026, a step up from the -79.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$38.57M+61.9% QoQ
- Last fiscal yearDec 2025
- -$136.54M-79.7% YoY
- LTMMar 2026
- -$158.55M-341.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -133.0% | -251.6% | -118.6 pp |
| 1 year | -79.7% | +63.0% | +142.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (136.54M) USD
- Year-over-year change
- -79.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (136.54M) | -79.7% |
| FY2024 | 2024-12-31 | (75.99M) | +67.7% |
| FY2023 | 2023-12-31 | (235.03M) | -690.0% |
| FY2022 | 2022-12-31 | 39.84M | +872.4% |
| FY2021 | 2021-12-31 | (5.16M) | — |
EBITDA vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -341.7% is the lowest of 9, against a peer median of +15.9%.
- EBITDA amounts to 8932.3% of revenue for RNAC, versus a peer median of 161.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.67M USD | +35.5% | — | 13.1% | |
| LTM Mar 2026 | -$14.84M USD | +39.0% | — | 102.5% | |
| LTM Mar 2026 | -$35.22M USD | — | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M USD | -75.7% | — | — |
| LTM Mar 2026 | -$50.77M USD | +11.7% | — | — | |
| LTM Mar 2026 | -$52.72M USD | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$69.83M USD | -147.0% | — | — | |
| LTM Mar 2026 | -$84.35M USD | -214.9% | — | 142957.6% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| LTM Mar 2026 | -$158.55M USD | -341.7% | — | 8932.3% | |
| Peer median (excluding RNAC) | — | +15.9% | — | 161.1% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 85.08M | 110.78M | 26M | 38.91M | 2.8M |
| Cost of Revenue | 0 | 2.04M | 0 | 0 | 0 |
| Gross Profit | 85.08M | 108.74M | 26M | 38.91M | 2.8M |
| Gross Margin | 100.0% | 98.2% | 100.0% | 100.0% | 100.0% |
| Research & Development | 68.74M | 72.38M | 71.26M | 45.11M | 58.03M |
| Selling, General & Admin | 20.94M | 23.86M | 40.45M | 30.13M | 31.47M |
| Operating Expenses | 89.67M | 94.2M | 112.42M | 82.81M | 89.5M |
| Depreciation & Amortization | 1.72M | 2.04M | 843K | 1.15M | 2.96M |
| EBITDA | (5.16M) | 39.84M | (235.03M) | (75.99M) | (136.54M) |
| EBITDA Margin | -6.1% | 36.0% | -903.8% | -195.3% | -4881.5% |
| Operating Income | (4.6M) | 14.54M | (86.42M) | (43.9M) | (86.71M) |
| Operating Margin | -5.4% | 13.1% | -332.3% | -112.8% | -3099.9% |
| Interest Income | 0 | 0 | 4.96M | 7.39M | 6.58M |
| Interest Expense | 2.84M | 3.03M | 2.83M | 0 | 0 |
| Other Income / Expenses | (5.12M) | 20.23M | (152.29M) | (33.24M) | (52.79M) |
| Income Before Tax | (9.72M) | 34.77M | (238.71M) | (77.14M) | (139.5M) |
| Pre-Tax Margin | -11.4% | 31.4% | -918.0% | -198.2% | -4987.3% |
| Income Tax Expense | 15.97M | (609K) | (19M) | 287K | (9.19M) |
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Net Margin | -30.2% | 31.9% | -844.9% | -199.0% | -4658.6% |
| EPS (Basic) | (6.74) | 7.33 | (49.76) | (2.99) | (5.02) |
| EPS (Diluted) | (6.60) | 3.00 | (49.76) | (3.29) | (5.02) |
| Weighted Avg Shares | 3.18M | 4.02M | 5.17M | 25.91M | 25.97M |
| Weighted Avg Shares (Diluted) | 3.18M | 4.05M | 5.17M | 23.69M | 25.97M |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.